SOLIRIS®
ABOUT SOLIRIS
Soliris is the first treatment to be approved to treat adults with anti-AChR Ab+ gMG in more than 60 years
Soliris works to help manage anti-acetylcholine receptor antibody-positive generalized Myasthenia Gravis (anti-AChR Ab+ gMG) by focusing on a specific part of your immune system.
In a clinical trial, some patients with gMG who responded to Soliris experienced early symptom improvement by 12 weeks.
- In a clinical trial of 125 patients, Soliris was shown to improve activities of daily living and muscle weakness in some patients with unresolved symptoms, despite multiple treatments
- Clinical response in this trial was defined as:
- ≥3-point improvement from baseline in MG-ADL total score at 26 weeks of treatment
- ≥5-point improvement from baseline in quantitative MG (QMG) total score at 26 weeks of treatment
- Of patients receiving Soliris (n=62) or placebo (n=63)
- MG-ADL: 60% reported an improvement in activities of daily living compared with 40% of those taking placebo
- QMG: 45% had a clinically meaningful improvement in muscle weakness compared with 19% of those taking placebo
- The 14-day infusion schedule for Soliris was carefully studied when determining safety and efficacy. It is important to follow your doctor’s prescribed treatment schedule and try to keep all of your infusion appointments within that 14-day time frame
In a clinical trial, some patients with gMG who responded to Soliris experienced early symptom improvement by 12 weeks.
- In a clinical trial of 125 patients, Soliris was shown to improve activities of daily living and muscle weakness in some patients with unresolved symptoms, despite multiple treatments
- Clinical response in this trial was defined as:
- ≥3-point improvement from baseline in MG-ADL total score at 26 weeks of treatment
- ≥5-point improvement from baseline in quantitative MG (QMG) total score at 26 weeks of treatment
- Of patients receiving Soliris (n=62) or placebo (n=63)
- MG-ADL: 60% reported an improvement in activities of daily living compared with 40% of those taking placebo
- QMG: 45% had a clinically meaningful improvement in muscle weakness compared with 19% of those taking placebo
- The 14-day infusion schedule for Soliris was carefully studied when determining safety and efficacy. It is important to follow your doctor’s prescribed treatment schedule and try to keep all of your infusion appointments within that 14-day time frame
In a clinical trial, some patients with gMG who responded to Soliris experienced early symptom improvement by 12 weeks.
- In a clinical trial of 125 patients, Soliris was shown to improve activities of daily living and muscle weakness in some patients with unresolved symptoms, despite multiple treatments
- Clinical response in this trial was defined as:
- ≥3-point improvement from baseline in MG-ADL total score at 26 weeks of treatment
- ≥5-point improvement from baseline in quantitative MG (QMG) total score at 26 weeks of treatment
- Of patients receiving Soliris (n=62) or placebo (n=63)
- MG-ADL: 60% reported an improvement in activities of daily living compared with 40% of those taking placebo
- QMG: 45% had a clinically meaningful improvement in muscle weakness compared with 19% of those taking placebo
- The 14-day infusion schedule for Soliris was carefully studied when determining safety and efficacy. It is important to follow your doctor’s prescribed treatment schedule and try to keep all of your infusion appointments within that 14-day time frame
Ask doctor about Soliris
Book Soliris Treatment